Oppenheimer Maintains Outperform on Cellectis, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Cellectis (NASDAQ:CLLS) but lowers the price target from $11 to $10.
June 12, 2024 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Cellectis but lowers the price target from $11 to $10.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100